Fungal Infection

First Topical Echinocandin Antifungal Granted QIDP, Fast Track Designation

By June 01, 2016

Cidara announced that the Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) status to its CD101 topical, for the proposed treatment for vulvovaginal candidiasis (VVC) and prevention of recurrent VVC (RVVC).